JP2010501188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501188A5 JP2010501188A5 JP2009525796A JP2009525796A JP2010501188A5 JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5 JP 2009525796 A JP2009525796 A JP 2009525796A JP 2009525796 A JP2009525796 A JP 2009525796A JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- rna molecule
- interfering rna
- nucleotides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 46
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 39
- 230000002452 interceptive effect Effects 0.000 claims 39
- 239000002773 nucleotide Substances 0.000 claims 26
- 125000003729 nucleotide group Chemical group 0.000 claims 26
- 108020004999 messenger RNA Proteins 0.000 claims 15
- 102100038367 Gremlin-1 Human genes 0.000 claims 12
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims 5
- 239000004055 small Interfering RNA Substances 0.000 claims 5
- 230000000699 topical effect Effects 0.000 claims 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000009368 gene silencing by RNA Effects 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 239000002924 silencing RNA Substances 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 108091081021 Sense strand Proteins 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 210000000795 conjunctiva Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83982606P | 2006-08-24 | 2006-08-24 | |
| PCT/US2007/076776 WO2008024983A2 (en) | 2006-08-24 | 2007-08-24 | Rnai-mediated inhibition of gremlin for treatment of iop-related conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501188A JP2010501188A (ja) | 2010-01-21 |
| JP2010501188A5 true JP2010501188A5 (enExample) | 2010-08-12 |
Family
ID=39032079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525796A Pending JP2010501188A (ja) | 2006-08-24 | 2007-08-24 | IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20080051361A1 (enExample) |
| EP (1) | EP2059597A2 (enExample) |
| JP (1) | JP2010501188A (enExample) |
| KR (1) | KR20090042297A (enExample) |
| CN (2) | CN101517081A (enExample) |
| AU (1) | AU2007286545A1 (enExample) |
| BR (1) | BRPI0715821A2 (enExample) |
| CA (1) | CA2659464A1 (enExample) |
| MX (1) | MX2009001896A (enExample) |
| WO (1) | WO2008024983A2 (enExample) |
| ZA (1) | ZA200900553B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| GB0708662D0 (en) * | 2007-05-04 | 2007-06-13 | Galapagos Nv | shRNA sequences |
| AU2008308784B2 (en) * | 2007-10-01 | 2013-07-18 | Arrowhead Research Corporation | Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders |
| BRPI0802525A2 (pt) | 2008-07-11 | 2010-03-09 | Kiyoshi Hashiba | endoscópio cirúrgico |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| WO2011072091A1 (en) * | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
| PL2796150T3 (pl) | 2011-12-15 | 2021-08-30 | Bioneer Corporation | Nowe koniugaty oligonukleotydowe i ich zastosowanie |
| KR101722948B1 (ko) | 2012-01-05 | 2017-04-04 | (주)바이오니아 | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 |
| RU2577227C1 (ru) | 2012-01-05 | 2016-03-10 | Байонир Корпорейшн | Высокоэффективная двухспиральная олиго-рнк конструкция типа наночастицы и способ ее изготовления |
| JP5906327B2 (ja) | 2012-01-18 | 2016-04-20 | バイオニア コーポレーションBioneer Corporation | 磁性ナノ粒子−SAMiRNA複合体およびその製造方法 |
| WO2013137686A1 (ko) * | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
| GB201215857D0 (en) * | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| AU2012389270B2 (en) * | 2012-09-05 | 2018-11-08 | Sylentis S.A.U. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| CA2917299C (en) | 2013-07-05 | 2020-07-21 | Bioneer Corporation | Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same |
| WO2015132303A1 (en) | 2014-03-04 | 2015-09-11 | Sylentis Sau | Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| JP2017200928A (ja) * | 2017-05-31 | 2017-11-09 | シレンティス・エセ・ア・ウ | siRNAならびに眼の状態の処置および/または予防のための方法および組成物におけるその使用 |
| CN106978509B (zh) * | 2017-06-07 | 2018-10-26 | 中南大学湘雅二医院 | 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966725A (zh) * | 2001-10-31 | 2007-05-23 | 爱尔康公司 | 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途 |
| US20040138163A1 (en) * | 2002-05-29 | 2004-07-15 | Mcswiggen James | RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| TW200639253A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
-
2007
- 2007-08-24 US US11/844,869 patent/US20080051361A1/en not_active Abandoned
- 2007-08-24 CA CA002659464A patent/CA2659464A1/en not_active Abandoned
- 2007-08-24 CN CNA2007800308171A patent/CN101517081A/zh active Pending
- 2007-08-24 KR KR1020097004684A patent/KR20090042297A/ko not_active Ceased
- 2007-08-24 WO PCT/US2007/076776 patent/WO2008024983A2/en not_active Ceased
- 2007-08-24 BR BRPI0715821-1A patent/BRPI0715821A2/pt not_active IP Right Cessation
- 2007-08-24 CN CN2012102535702A patent/CN102743767A/zh active Pending
- 2007-08-24 AU AU2007286545A patent/AU2007286545A1/en not_active Abandoned
- 2007-08-24 EP EP07841339A patent/EP2059597A2/en not_active Withdrawn
- 2007-08-24 ZA ZA200900553A patent/ZA200900553B/xx unknown
- 2007-08-24 MX MX2009001896A patent/MX2009001896A/es active IP Right Grant
- 2007-08-24 JP JP2009525796A patent/JP2010501188A/ja active Pending
-
2010
- 2010-06-02 US US12/791,926 patent/US20100305193A1/en not_active Abandoned
-
2011
- 2011-10-26 US US13/281,785 patent/US20120077864A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008130857A (ru) | Опосредованное phkи ингибирование hif1a для лечения глазного ангиогенеза | |
| RU2008150324A (ru) | Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний | |
| RU2011124528A (ru) | ОПОСРЕДОВАННОЕ PHKI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ | |
| JP2008525460A5 (enExample) | ||
| Guzman‐Aranguez et al. | Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy | |
| RU2007132874A (ru) | Phki-опосредованное ингибирование мишеней повышенного внутриглазного давления | |
| CN110846316A (zh) | 在基因沉默中具有降低的脱靶效应的una寡聚物 | |
| JP2009533475A5 (enExample) | ||
| JP2009540011A5 (enExample) | ||
| JP2012072152A5 (enExample) | ||
| US20100305193A1 (en) | Rnai-mediated inhibition of gremlin for treatment of iop-related conditions | |
| JP2010540564A5 (enExample) | ||
| JP2022185052A5 (enExample) | ||
| JP2006505251A5 (enExample) | ||
| RU2010117178A (ru) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний | |
| JP2013540770A5 (enExample) | ||
| JP2008533050A5 (enExample) | ||
| JP2022501044A5 (enExample) | ||
| US20150057336A1 (en) | RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA | |
| JP2009533466A5 (enExample) | ||
| WO2015030616A4 (en) | Use of nucleic acid molecules in therapy of diseases induced by expansion of trinucleotide cag repeats | |
| KR20180039760A (ko) | siRNA, 및 NRARP 유전자의 발현을 억제하기 위한 방법 및 조성물에서의 이의 용도 | |
| CN101124322B (zh) | 用于治疗青光眼的血清淀粉状蛋白A的RNAi抑制 | |
| JP2024526234A5 (enExample) | ||
| WO2008092142A2 (en) | Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization |